Anti-SARS-CoV Spike (17aa – Intermediate Domain)

Anti-SARS-CoV Spike (17aa – Intermediate Domain)

Product No.: S542

[product_table name="All Top" skus="S542"]

- -
- -
Target
SARS Spike
Product Type
Polyclonal Antibody
Alternate Names
SARS-CoV Spike Antibody: E2, Spike glycoprotein, E2, S glycoprotein
Isotype
IgG
Applications
ELISA
,
WB

- -
- -
Product Size

Data

Direct ELISA
- -
- -

Antibody Details

Product Details

Reactive Species
Virus
Host Species
Rabbit
Immunogen
Anti-SARS-CoV Spike antibody was raised against a peptide corresponding to 17 amino acids near the center of SARS-CoV Spike glycoprotein. The immunogen is located within amino acids 550-600 of SARS-CoV Spike.
Product Concentration
0.5 mg/ml
Formulation
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Storage and Handling
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
WB
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Rabbit Anti- Severe Acute Respiratory Syndrome Spike (SARS-CoV Spike) recognizes an epitope in the intermediate domain of SARS Spike. This polyclonal antibody was purified using affinity chromatography.
Background
A novel coronavirus has recently been identified as the causative agent of SARS-CoV.1-2 Coronaviruses are a major cause of upper respiratory diseases in humans.3 The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.4

Antigen Details

Research Area
COVID-19
.
Seasonal and Respiratory Infections
.
Viral

References & Citations

1. Marra, M. A. et al. (2003) Science 300:1399 2. Rota, P. A. et al. (2003) Science 300:1394 3. Navas-Nartin, S. R. et al. (2004) J. Neurovirol. 10:75 4. Li, W. et al. (2003) Nature 426:450
Indirect Elisa Protocol
General Western Blot Protocol
Products are for research use only. Not for use in diagnostic or therapeutic procedures.